针对阿尔茨海默病的药物重新定位,整合了全转录组关联研究和生物网络分析
Xin Wang1,2, Meng Wang3, Han Wang4
1College of Information Science and Engineering, Northeastern University, Shenyang, China.
Journal of Alzheimer's disease : JAD
|July 23, 2025
概括
这项研究通过分析生物网络,确定了43种潜在的候选药物,包括巴里西丁尼和 gabapentin,用于阿尔茨海默病 (AD) 治疗. 这些发现为这种神经退行性疾病提供了新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 计算生物学 计算生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 的特点是蛋白质沉积和分子异常.
- 目前针对阿尔茨海默病的治疗方法缺乏改变疾病的疗效.
研究的目的:
- 通过基于网络的药物重新定位策略,识别阿尔茨海默病的潜在治疗方法.
- 针对关键的蛋白质和生物途径,涉及到AD病理.
主要方法:
- 构建了AD相关分子及其调节相互作用的综合生物网络.
- 来自GWAS,MRI衍生的表型,生物分子相互作用和基因表达特征的综合数据.
- 利用计算方法对药物进行重新定位.
主要成果:
- 在AD患者中发现了转录因子与改变基因表达之间的显著相关性.
- 根据它们的作用机制优先考虑候选药物.
- 确定了43种候选药物 (28种FDA批准,15种实验),包括巴里西替尼和 gabapentin,针对大脑皮质和海马体等脑部区域的AD病理.
结论:
- 这项研究表明,有希望的系统性药物重定向策略可以用于识别新的AD治疗方法.
- 这种方法结合了网络分析和MRI驱动的研究,为其他神经系统疾病提供了潜力.
更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
983
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
27.1K
相关概念视频
01:26Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
01:22Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262